Shersar @Shersar1

#Dibujandocaminos #Kassumay Papá-Familia-Oncología Ycosasvariasquepuedenserinteresantes Joined October 2018

Tweets

477
Followers

46
Following

909
Likes

9K

Shersar @Shersar1

2 years ago

@Asesor_Biwenger @asesorSFC Una duda crack! Entre Moleiro, Sancet y Miovski tengo que elegir a 2? Que me recomiendas? Gracias

1 0 0 171 0

View Details

Shersar @Shersar1

2 years ago

@ElBielsaFantasy @futbol_fantasy Una duda crack! Entre Moleiro, Sancet y Miovski tengo que elegir a 2? Que me recomiendas? Gracias

1 0 0 250 0

View Details

Toni Roldán Monés @toniroldanm

3 years ago

¡Buenos días! Desde @EsadeEcPol nos propusimos dedicar los esfuerzos en campaña a hacer tribunas con propuestas concretas de mejoras de políticas públicas: profes, dependencia, unis, jovenes, pensiones… Aprovecho la jornada de reflexión para compartirlas con vosotros Va 🧶

5 56 183 61K 75

View Details

Marcos Vazquez - Fitness Revolucionario @FITrebelde

3 years ago

Si quieres tener mejores resultados que la mayoría de personas, debes hacer cosas que la mayoría de personas no están dispuestas a hacer. En el caso de la salud, física y mental, hay unos pocos hábitos sencillos que te harán estar mejor que el 95% de la población.

8 68 413 30K 29

View Details

Elisabetta Munzone @elisabettasabet

3 years ago

📢 Finally out ‼️Oral VEX (Vinorelbine, Cyclophosphamide, and Capecitabine) vs Paclitaxel for Metastatic ER+/ERBB2− Breast Cancer improves TTF & PFS jamanetwork.com/journals/jamao… @etop_ibcsg @IEOufficiale #metronomicVEX; #breastcancer #noalopecia #oralchemotherapy

0 19 52 7K 4

View Details

Knowuro @knowuro

3 years ago

Hello #urologists! 👋 It's finally here! 🎉 our flowchart about Prostate Cancer 2023! You can download it here: knowuro.com/goodies Thank you @JGomezRivas for your incredible collaboration! 🙏 #prostatecancer #urology #guidelines

4 130 354 46K 125

View Details

Dr. Gustavo Nader Marta, MD, PhD @Marta_GustavoN

3 years ago

Palliative RT is effective in providing tumor re- sponse and symptom relief in patients with incur- able HNC. Considering the differences detected by the meta-analysis, short RT courses with a high BED using IMRT or SBRT can improve the ther- apeutic index of RT.

1 14 46 3K 11

View Details

Paolo Tarantino @PTarantinoMD

3 years ago

The formatted version of the ESMO Consensus Statements on HER2-low breast cancer is finally published on @Annals_Oncology. We hope it will prove helpful to navigate the evolving landscape of HER2-low breast cancer & to prepare for further upcoming changes! annalsofoncology.org/article/S0923-…

3 89 223 47K 24

View Details

Baricorcho @Baricorcho

3 years ago

Unmet need in HR-pos HER2-neg early breast cancer. High risk patients deserve new approaches. The dDFS and OS rates at 5 years were 77.4% and 88.8%; and at 10 years were 59.7% and 70.9%. @GEICAM pubmed.ncbi.nlm.nih.gov/37338729/

1 10 20 3K 0

View Details

Yüksel Ürün @DrYukselUrun

3 years ago

Can radiotherapy for primary #breastcancer increase the risk of secondary breast cancer in patients with BRCA1/2 gene mutations? 🧬☢️Radiation therapy for breast cancer may increase risk of contralateral breast cancer in BRCA1/2 carriers. 🧬☢️A study of 3,600 BRCA1/2 carriers found that those who received radiation therapy were more likely to develop contralateral breast cancer than those who did not. The risk was higher for BRCA2 carriers than BRCA1 carriers. 🧬☢️The study's authors say that radiation therapy regimens that minimize the dose to the contralateral breast should be considered for BRCA1/2 carriers. Any comment for primary treatment of #prostatecancer ? @JNCI_Now @ASCO @myESMO @OncoAlert @OncBrothers @ASTRO_org @ESTRO_RT @PCFnews doi.org/10.1093/jnci/d…

2 44 86 15K 15

View Details

Arndt Vogel @ArndtVogel

3 years ago

Lenvatinib Plus Pembrolizumab vs Regorafenib or TAS for Previously Treated mCRC: Phase 3 LEAP-017 Study at #WCGIC2023 👉mOS: 9.8 vs 9.3 mo 👉There is some activity, but⛔️ 👉IO in MSS CRC remains a challenge... @WCGIC @myESMO @OncoAlert

3 57 122 22K 13

View Details

Alejandro Jodorowsky @alejodorowsky

3 years ago

Un sabio...

6 181 962 48K 14

View Details

Raffaele Giusti @oncoblogger

3 years ago

NGS does not seem to be valuable when performed in cases with a poor PS, rapidly progressing cancer, short expected lifetime, or cases with no standard therapeutic options. No excuses or illusions please.

6 96 198 39K 38

View Details

Oncology Brothers @OncBrothers

3 years ago

Day 2 #ASCO23 Highlights: 1. #KN671: PeriOp pembro in resectable NSCLC 2. #KN826: Chemo + IO in cervical Ca 3. #DUOO: IO/PARPi ovarian cancer patients in 1L #lcsm @ASCO @OncoAlert #OncTwitter #MedTwitter #gyncsm 1/4

1 83 211 60K 38

View Details

Angela Lamarca @DrAngelaLamarca

3 years ago

🗣️ #PRO data at #ASCO23 supports that treatment toxicity does NOT worsen patients’ quality of life 1️⃣IMBRAVE-050- Atezo-Bev in resected/ablated #HCC - NO signif detriment with Atezo-Bev 2️⃣KEYNOTE-966 - Pembro+CisGem in 1st line #aBTC - SIMILAR time to det with Pembro #ASCO23

0 10 20 2K 2

View Details

Oncology Brothers @OncBrothers

3 years ago

Day 1 #ASCO23 Highlights: 1. #NATALEE: Adj #ribociclib HR+ breast Ca 2. MONARCHE: Adj #abemaciclib update 3. #ATTRACTION5: Adj Gastric Ca 4. #IMbrave050: Adj HCC 5. OFS in Premenopausal 6. #IMerge imetelstat MDS @ASCO @OncoAlert #bcsm #gism #OncTwitter #MedTwitter 1/7

11 149 476 98K 86

View Details

Sara Tolaney @stolaney1

3 years ago

NATALEE Adjuvant Ribo in early stage HR+ BC Median f/u 34.0 months 57% at ≥2 ys, 20% at 3 yrs iDFS: 90.4% vs 87.1% HR 0.748 p=0.0014 Stage 2 HR 0.76, Stage 3 HR 0.74 DDFS: 90.8% vs 88.6% HR 0.739 G≥3 Tox: Neutropenia: 43.8% Liver AEs: 8.3% #ASCO23 @OncoAlert

1 30 75 9K 8

View Details

Paolo Tarantino @PTarantinoMD

3 years ago

Novel SERDs: where are we? One agent approved (elacestrant) with positive phase 3 data and clinically meaningful PFS among patients with ESR1-mutant & endocrine-sensitive tumors. Promising randomized data (ph2) also with camizestrant. No benefit with girerestrant or amcenestrant.

1 15 52 6K 7

View Details

Paolo Tarantino @PTarantinoMD

3 years ago

Which should be the duration of adjuvant endocrine treatment for early-stage HR+ breast cancer? @MichaelGnant nicely recapitulates the evidence & highlights the recent votes by the St. Gallen panel, with fairly clear answers. #ASCO23

3 48 126 12K 12

View Details

Paolo Tarantino @PTarantinoMD

3 years ago

Brilliant discussion of #NATALEE by Nadia Harbeck. Key points: 1) we now have 2 CDK4/6i that significantly improve iDFS; 2) more follow up needed to confirm the benefit (>80% of patients in NATALEE are still on ribo), 3) don’t forget to test for gBRCA1/2! #ASCO23 #bcsm